Fredun Pharma (539730)
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹827.85 |
| Market Cap | ₹397.59 Cr |
| P/E Ratio | 25.6 |
| ROCE | 18.94% |
| ROE | 26.02% |
| Dividend Yield | 0.04% |
| Profit Growth | 96.62% |
| Debt/Equity | — |
| Sales Growth | 56.7% |
| 52-Week Range | ₹1,362.15 — ₹2,620 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹256.63 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me start with what I admire: Fredun Pharma earns a return on equity of 26% and a return on capital employed of nearly 19%. That is real capital efficiency, and it is the first thing I look for. Sales grew 56.7% and profits jumped 96.6%. The PEG ratio of 0.33 tells me the market's 25.6 times earnings is not pricing in continued growth. The Piotroski score of 7 out of 9 also suggests a financially disciplined business, not a cash burner.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer